In Vivo - Strategic Analysis For Medtech And Pharma Leaders since 1981
Podcasts
• By
In this episode of the In Vivo podcast Michelle Werner, CEO of Alltrna, discusses using tRNA as a therapeutic modality for rare diseases.
Growth
Innovation
• By
InSilico Medicine hopes its open-source LLM will be the “one model to guide them all” as industry moves towards artificial biomedical intelligence and interest in longevity grows.
• By
The time is now to prepare your company for AI implementation. Doing so starts with the C-suite.
Market Access
• By
As the US biosimilars market approaches the end of its first decade, it has seen another busy year, with Amgen’s surprise launch of a rival to Eylea shaking up expectations as other first-time approvals rolled in throughout 2024. Meanwhile, competition to Stelara is waiting in the wings from the start of 2025.